Manufacturer record
Levotic Pharma: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Levotic Pharma were declared Not of Standard Quality in February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: LPC25138, Pregabalin capsules IP 300mg (exp Nov 2027). SDTL, Punjab (state lab) found it not of standard quality: The contents of Pregabalin found to be 345.40mg per Capsule (115.13%) against labeled claim of 300.0mg per capsule. Listed in the February 2026 alert.
Records by type
2 records linked to Levotic Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Pregabalin capsules IP 300mg | Batch LPC25138Mfg Dec 2025 · Exp Nov 2027 | The contents of Pregabalin found to be 345.40mg per Capsule (115.13%) against labeled claim of 300.0mg per capsule.Labelling | SDTL, PunjabState lab | Feb 2026 |
| Gabapentin capsules IP 400mg | Batch LPC25029Mfg Feb 2025 · Exp Jan 2027 | Description and Uniformity of WeightDescription | SDTL, PunjabState lab | Feb 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.